Back to results
US 12,691,171 B2Granted
Coronavirus vaccine formulations
OwnerGale Smith, Michael J. Massare +1inventors
InventorsGale Smith, Michael J. Massare, Jing-Hui Tian
Life of this patent
Estimating the term…
Abstract
Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
Claims30
A coronavirus (CoV) Spike(S) glycoprotein comprising:
- (i) an S1 subunit comprising an inactivated furin cleavage site having the amino acid sequence of QQAQ (SEQ ID NO:
- 7);
- wherein the S1 subunit comprises an N-terminal domain (NTD);
- a receptor binding domain (RBD), and subdomains 1 and 2 (SD1/2);
- wherein the N-terminal domain comprises up to about 20 modifications compared to a NTD of a CoV S glycoprotein of SEQ ID NO:
- 2;
- wherein the RBD comprises up to about 30 modifications compared to a RBD of a CoV S glycoprotein of SEQ ID NO:
- 2;
- wherein the SD1/2 comprises up to about 15 modifications compared to a SD1/2 of a CoV S glycoprotein of SEQ ID NO:
- 2;
- and
- (ii) an S2 subunit, wherein amino acids 973 and 974 are proline,
- wherein the S2 subunit comprises up to 15 additional modifications compared to the S2 subunit of a CoV S glycoprotein of SEQ ID NO:
- 2;
- wherein the amino acids of the CoV S glycoprotein are numbered with respect to the CoV S glycoprotein of SEQ ID NO:
- 2;
- wherein each modification is a mutation, deletion, or addition of one amino acid.
14 more elements
Dependencies are inferred from the claim text.